Ketamine for Refractory Chronic Migraine: a Pilot Study
NCT03896256
Completed
Ketamine is a drug used for anesthesia but at low doses it is a very effective pain reliever in several chronic conditions. Preliminary studies have shown that ketamine might be effective for patients with refractory chronic migraine, which is a severe type of headache for which patients usually have tried and failed many medications and can cause severe disability to their lives. This study will evaluate ketamine prospectively when given to patients who have "failed" an initial inpatient treatm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/09/2020
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Migraine Headache With Intractable Migraine
Register for Updates
Ketamine for Depression and Alcohol Dependence
NCT01551329
Completed
The purpose of this study is to evaluate the efficacy of ketamine in reducing depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence. The investigators hypothesize the following for the present study: A single dose of ketamine will induce a rapid, robust and sustained reduction in depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence relative to placebo as defined by change in Hamilton Depression Rating Scale tot... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
03/05/2020
Locations: VA CT Healthcare Systems, West Haven, Connecticut
Conditions: Depression, Alcohol Dependence
Register for Updates
Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy
NCT02452060
Completed
This is a randomized, double-blind, placebo-controlled, two-arm parallel, single-center study. One hundred subjects (50 in each arm) will be enrolled. Subjects, between the ages 18 and 65, undergoing laparoscopic gastric bypass or sleeve gastrectomy will be recruited and consented during the preadmission visit prior to surgery.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/02/2020
Locations: NYU Langone Medical Center, New York, New York
Conditions: Pain, Postoperative Depression
Register for Updates
Ketamine for Suicidality in Bipolar Depression
NCT01944293
Completed
This study is designed to compare the effectiveness of two medications, Ketamine and Midazolam, for rapidly relieving suicidal thoughts in people suffering from bipolar depression. The first drug, ketamine, is an experimental antidepressant that early studies have shown may quickly reduce suicidal thoughts, but we are not sure how well it may work. Midazolam, the comparison drug, is not thought to reduce depression or suicidal thoughts.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/27/2020
Locations: Columbia University/New York State Psychiatric Institute, New York, New York
Conditions: Bipolar Disorder, Major Depressive Episode, Suicidal Ideation
Register for Updates
Glutamatergic Modulation of Disordered Alcohol Use
NCT02539511
Completed
Alcohol use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered drinking. Alcohol use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational... Read More
Gender:
ALL
Ages:
Between 21 years and 69 years
Trial Updated:
01/31/2020
Locations: NYSPI, New York, New York
Conditions: Alcohol Dependence
Register for Updates
Facilitating the Behavioral Treatment of Cannabis Use Disorder
NCT02946489
Completed
Cannabis use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered cannabis use. Cannabis use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this single blind open-label trial is to test the feasibility of administering glutamate modulators in conjunction... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
01/31/2020
Locations: NYSPI, New York, New York
Conditions: Cannabis Dependence
Register for Updates
Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy
NCT02643979
Terminated
Propofol is one of the most popular anesthetic drugs used for sedation during upper gastrointestinal endoscopies due to its quick onset and quick resolution of symptoms allowing patients to leave the hospital sooner. However, when administered it can also slow the breathing of patients and cause others to have upper airway obstruction (such as snoring) which can impede proper spontaneous breathing. Ketamine is an agent that is capable of providing both pain control and sedation while having eith... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2020
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Obesity, Bariatrics, Sleep Apnea Syndromes, Gastric Bypass, Endoscopy
Register for Updates
Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients
NCT02432456
Completed
This study will evaluate the effectiveness of ketamine infusions in the management of acute pain resulting from broken ribs suffered following a blunt trauma. Half of patients will receive the institutional standard of care and a placebo infusion (no active medication). The other half of patients will receive the institutional standard of care and a ketamine infusion. All subjects and staff will be blinded as to whether they are receiving placebo or ketamine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2020
Locations: Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin
Conditions: Wounds and Injuries, Rib Fractures
Register for Updates
Ketamine in Adolescents With Treatment-Resistant Depression
NCT02078817
Completed
This study will test the use of ketamine for treatment of depression in adolescents that have not responded to other treatments. We will also examine neurobiological mechanisms of treatment.
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
01/24/2020
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Major Depressive Disorder
Register for Updates
Endogenous Opioid Modulation by Ketamine
NCT03051945
Withdrawn
Demonstrate the acute effects of ketamine on endogenous µ-opioid neurotransmission in humans.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/24/2020
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Major Depressive Disorder
Register for Updates
Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea
NCT03109418
Terminated
The aim of this study is to substantially reduce overall postoperative morbidity and mortality associated with obstructive sleep apnea.
Gender:
ALL
Ages:
Between 19 years and 100 years
Trial Updated:
12/18/2019
Locations: UAB Department of Anesthesiology and Perioperative Medicine, Birmingham, Alabama
Conditions: Sleep Apnea, Obstructive Sleep Apnea, Postoperative Complications
Register for Updates
Ketamine in the Treatment of Depression
NCT01558063
Completed
Depressed patients will be offered experimental treatment with a new, potentially fast-acting antidepressant called ketamine while being scanned by magnetic resonance imaging (MRI) to measure the chemical effect of the drug. Ketamine will be given in a dose of 0.0 (placebo), 0.1, 0.2, 0.3, 0.4, or 0.5 mg/kg. If a patient does not respond to ketamine after the first infusion, it may be because s/he received ketamine placebo or the dose of ketamine was too low. In that case, an optional second sca... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/03/2019
Locations: New York State Psychiatric Institute, New York, New York
Conditions: Major Depressive Disorder
Register for Updates